These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Sayanagi K; Sharma S; Yamamoto T; Kaiser PK Ophthalmology; 2009 May; 116(5):947-55. PubMed ID: 19232732 [TBL] [Abstract][Full Text] [Related]
4. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J; Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377 [TBL] [Abstract][Full Text] [Related]
5. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of an Artificial Intelligence-Based Detector of Sub- and Intraretinal Fluid on a Large Set of Optical Coherence Tomography Volumes in Age-Related Macular Degeneration and Diabetic Macular Edema. Habra O; Gallardo M; Meyer Zu Westram T; De Zanet S; Jaggi D; Zinkernagel M; Wolf S; Sznitman R Ophthalmologica; 2022; 245(6):516-527. PubMed ID: 36215958 [TBL] [Abstract][Full Text] [Related]
7. Risk of scar in the comparison of age-related macular degeneration treatments trials. Daniel E; Toth CA; Grunwald JE; Jaffe GJ; Martin DF; Fine SL; Huang J; Ying GS; Hagstrom SA; Winter K; Maguire MG; Ophthalmology; 2014 Mar; 121(3):656-66. PubMed ID: 24314839 [TBL] [Abstract][Full Text] [Related]
8. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Lee JY; Folgar FA; Maguire MG; Ying GS; Toth CA; Martin DF; Jaffe GJ; Ophthalmology; 2014 Dec; 121(12):2423-31. PubMed ID: 25064723 [TBL] [Abstract][Full Text] [Related]
9. Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Kashani AH; Keane PA; Dustin L; Walsh AC; Sadda SR Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3366-73. PubMed ID: 19168893 [TBL] [Abstract][Full Text] [Related]
10. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG; Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282 [TBL] [Abstract][Full Text] [Related]
11. A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices. Michl M; Neschi M; Kaider A; Hatz K; Deak G; Gerendas BS; Schmidt-Erfurth U Eye (Lond); 2023 Aug; 37(12):2573-2579. PubMed ID: 36577804 [TBL] [Abstract][Full Text] [Related]
12. Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Querques G; Forte R; Berboucha E; Martinelli D; Coscas G; Soubrane G; Souied EH Ophthalmic Res; 2011; 46(3):152-9. PubMed ID: 21389740 [TBL] [Abstract][Full Text] [Related]
13. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Willoughby AS; Ying GS; Toth CA; Maguire MG; Burns RE; Grunwald JE; Daniel E; Jaffe GJ; Ophthalmology; 2015 Sep; 122(9):1846-53.e5. PubMed ID: 26143666 [TBL] [Abstract][Full Text] [Related]
14. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Major JC; Wykoff CC; Mariani AF; Chen E; Croft DE; Brown DM Retina; 2014 Jan; 34(1):48-54. PubMed ID: 23764967 [TBL] [Abstract][Full Text] [Related]
15. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685 [TBL] [Abstract][Full Text] [Related]
16. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E; Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329 [TBL] [Abstract][Full Text] [Related]
17. Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT. Toth CA; Tai V; Pistilli M; Chiu SJ; Winter KP; Daniel E; Grunwald JE; Jaffe GJ; Martin DF; Ying GS; Farsiu S; Maguire MG; Ophthalmol Retina; 2019 Apr; 3(4):316-325. PubMed ID: 31014683 [TBL] [Abstract][Full Text] [Related]
18. Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results. Michalewski J; Nawrocki J; Izdebski B; Michalewska Z Indian J Ophthalmol; 2014 May; 62(5):554-60. PubMed ID: 24881600 [TBL] [Abstract][Full Text] [Related]
19. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Joeres S; Tsong JW; Updike PG; Collins AT; Dustin L; Walsh AC; Romano PW; Sadda SR Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4300-7. PubMed ID: 17724220 [TBL] [Abstract][Full Text] [Related]
20. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Chan CK; Jain A; Sadda S; Varshney N Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]